Tag Archives: Cancer Facts & Figures”

Turkey Lurkey Thanksgiving Title

Posted on by
Reply

Traditionally, Thanksgiving is best known as the Holiday that the Detroit Lions get the “stuffing” knocked out of them

However, this year, it’s time to tender the tainted twisted trophy of Thanksgiving Turkey-Lurkey to Detroit’s toasted triumvirate treat of two-faced twerk-salad troll turpitude, and I have the temerity to tinker and tamper until I pay tribute with therapeutic levels of Thoreauness in response to GorskGeek’s misinformation, disinformation, and MisDisInformation (Missed ‘Dis Information)

Wednesday, 12/21/2005, Indianapolis, Indiana-based Eli Lilly and Company was treated to truthification, in connection with their illegal promotion (misbranding) of pharmaceutical drug EVISTA; (FDA approved for prevention and treatment of osteoporosis in post-menopausal women), in the:

a. prevention in risk of breast cancer

b. reduction in risk of breast cancer

Alleged in information, promoted drug as effective for reducing risk of breast cancer EVEN AFTER PROPOSED LABELING FOR THIS USE SPECIFICALLY REJECTED by FDA [1]

GorskGeek, being the breast cancer oncology specialist he claims to be, and so concerned about breast cancer patients that he is that “guy” who speaks out passionately about issues like the 10-year American Cancer Society Cancer Facts & Figures, “Estimated Breast Cancer Deaths for Women”, which reflect that in 2002, 39,600 (15%) women were estimated to die from breast cancer, and this year, 2013, the estimate is 39,620 (14%), which is 20 women MORE than 10-years ago, and who rails tirelessly about the ACS’s “Estimated New Breast Cancer cases in Women”, which 10-years ago was 203,500 (31%) in 2002, and now, in 2013 is 232,340 (29%), which is ONLY
28,840 MORE than 10-years ago [2]

Now THAT’s progress !

GorskGeek, of course, must accomplish all this under his breath

But I’m sure you’re wondering, dear reader, what was GorskGeek’s outraged blog about this American pharmaceutical manufacturer coughing up $36 MILLION ?

Well, let me tell you … just as soon as I find it

Wait for it

Wait for it

Wait for it

GorskGeek was unable to bring himself to blog about Evista until exactly one year later, on 12/21/2006, and even then, he was “mum’s the word” about the breast cancer claims [3]

Perhaps GorskGeek just “knew” that eventually Evista would finally be approved by the FDA for Eli Lilly’s preventing or reducing risk of breast cancer claims on 9/13/2007, and who were those paper-pushing FDA apparatchiks to prevent Lilly from implementing their “Internal business plan” ? [4-9]

GorskGeek wouldn’t want to damage his slim and non-existent chance of getting some Eli Lilly money for research, by blogging anything that might in any way be possibly construed as him saying anything negatory about the BIG Pharma teat he longs to suck off of

After all, Bob ‘n’ Weave Blaskiewicz (who sees every molehill as a mountain), did say about GorskGeek, 9/28/2013 [10]:
——————————————————————
1:58:04
——————————————————————
“But he is a, the thing is, the thing is, you thing you have to understand is Gorski, Gorski is a genuine expert, in matters re re regarding on oncology studies“

“I mean, he has a”

“He, He’s able to convince people, he’s able to convince people, on the strength of his record, to give him money to carry out research”

“People who know what they’re talking about”

“To give him money to carry out his research”

“Right ?”
——————————————————————
1:59:00
——————————————————————
Yeah, right

Bobby 🙂

GorskGeek is hoping for a Happy Thanksgiving Golden Parachute; which is where he helps whistleblow about illegal BIG Pharma activity regarding some drug(s), which leaves him as the beneficiary of some funds like Mr. H. Dean Steinke, former Merck employee and his $68,190,000 MILLION from the federal government and states share of settlement amounts:
——————————————————————
$44,690,000 MILLION – Mr. H. Dean Steinke, former Merck employee from federal share of settlement amount (1997 – 2001)
——————————————————————
$23.5 MILLION – Mr. H. Dean Steinke, former Merck employee from the states share of settlement amount (1997 – 2001)
——————————————————————
Next, GorskGeek goes off on his fave autism prescription antipsychotic drug Risperdal, and the 11/4/2013, Monday, allegations concerning Global health care giant Johnson & Johnson (J&J) and its subsidiaries, $2.2 BILLION + fine regarding J&J Subsidiary Janssen (1999 – 2005) actions [11]
======================================
REFERENCES:
======================================
[1] – 12/21/2005
——————————————————————
EVISTA (FDA approved for prevention and treatment of osteoporosis in post-menopausal women)
——————————————————————
Eli Lilly and Company, Indianapolis, Indiana-based company
——————————————————————
12/21/2005, Wednesday
——————————————————————
$36 MILLION
——————————————————————
In connection with illegal promotion of pharmaceutical drug
——————————————————————
Pleading guilty to criminal count of violating Food, Drug, and Cosmetic Act by misbranding drug
——————————————————————
In addition to criminal plea
agreed to settle civil Food, Drug, and Cosmetic Act liabilities by entering into consent decree of permanent injunction
——————————————————————
Charged in criminal information filed with violation of Food, Drug, and Cosmetic Act, following investigation by Food and Drug Administration’s (FDA) Office of Criminal Investigations
——————————————————————
Plea agreement signed by Lilly and United States

Complaint for permanent injunction

Consent decree of permanent injunction signed by company and United States
——————————————————————
Information alleges 1st year’s sales of drug in U.S. were disappointing compared to original forecast
——————————————————————
According to information
10/1998 – company reduced forecast of drug’s 1st year’s sales in U.S. from $401 million to $120 million
——————————————————————
Internal business plan noted:

“Disappointing year versus original forecast.”
——————————————————————
Information alleges in order to expand sales of drug, Lilly sought to broaden market for drug by promoting it for unapproved uses
——————————————————————
Information alleges strategic marketing plans and promotion touted drug as effective in preventing and reducing risk of diseases for which drug’s labeling lacked adequate directions for use
——————————————————————
According to information: Evista
1. brand team
2. sales representatives
promoted drug for:
a. prevention in risk of breast cancer
b. reduction in risk of breast cancer
c. reduction in risk of cardiovascular disease
——————————————————————
Under provisions of Food, Drug, and Cosmetic Act, drug misbranded when labeling didn’t bear adequate directions for each of intended uses
——————————————————————
Alleged in information, promoted drug as effective for reducing risk of breast cancer even after proposed labeling for this use specifically rejected by FDA
——————————————————————
Information alleges executed illegal conduct using number of tactics, including:

1. One-on-one sales pitches by sales representatives promoting drug to physicians about off-label uses of drug

2. Sales representatives trained to prompt or bait questions by doctors in order to promote drug for unapproved uses

3. Encouraging sales representatives promoting drug to send unsolicited medical letters to promote drug for unapproved use to doctors on their sales routes

4. Organizing “market research summit’ during which drug was discussed with physicians for unapproved uses, including reducing risk of breast cancer

5.
a. Creating
b. distributing
to sales representatives “Evista Best Practices” videotape, in which sales representative states “Evista truly is the best drug for the prevention of all these diseases” referring to:

1). osteoporosis
2). breast cancer
3). cardiovascular disease
——————————————————————
Complaint for permanent injunction alleges executed illegal conduct using number of tactics, including:

1. Training sales representatives to promote drug for prevention and reduction in risk of breast cancer by use of medical reprint in way that highlighted key results of drug and thereby promoted drug to doctors for unapproved use

2. Some sales representatives were instructed to hide disclosure page of reprint which noted:

a. “All of the authors were either employees or paid consultants of Eli Lilly at the time this article was written,”

b. “The prescribing information provides that “The effectiveness of [Evista] in reducing the risk of breast cancer has not yet been established.””

3. Organizing “consultant meetings” for physicians who prescribed drug during which unapproved uses of drug discussed

4. Calculating incremental new prescriptions for doctors who attended Evista advisory board meetings in 1998

5. advisory board meetings included discussion of unapproved uses for drug

6. By measuring and analyzing incremental new prescriptions for doctors who attended advisory board meetings, Lilly was using this intervention as tool to promote and sell drug
——————————————————————
In addition to agreeing to plead guilty to criminal information and plea agreement signed by Lilly, settlement with United States includes following components:

(a) agreed to settle civil Food, Drug, and Cosmetic Act liabilities by entering into consent decree of permanent injunction

(1). As part of consent decree, agreed to comply with terms of permanent injunction, which will require company to implement effective training and supervision of marketing and sales staff for drug, and ensure any future off-label marketing conduct is detected and corrected

(2). agreed to be permanently enjoined from directly or indirectly promoting drug for use in:

a. preventing or reducing risk of breast cancer

b. reducing risk of cardiovascular disease

c. or for any other unapproved use in manner that violates Food, Drug, and Cosmetic Act unless and until FDA approves drug for additional use or uses
——————————————————————
(b) as part of consent decree, agreed to hire and utilize independent organization to conduct reviews to assist Lilly in assessing and evaluating Lilly’s

1. systems
2. processes
3. policies
4. procedures
relating to promotion of drug and company’s compliance with consent decree
——————————————————————
FDA made following announcement to postmenopausal women who have taken drug for prevention or treatment of osteoporosis:
——————————————————————
“No postmenopausal woman who has taken Evista for the prevention or treatment of osteoporosis is affected by this action, as this matter today relates only to unapproved uses of Evista.”
——————————————————————
Defendant agreed to plead guilty to charge in information
——————————————————————
Defendant agreed to resolve complaint for permanent injunction by agreeing to consent decree of permanent injunction
——————————————————————
http://www.justice.gov/opa/pr/2005/December/05_civ_685.html
======================================
[2] – 11/13/2013 – The War on Cancer (I don’t think it means, what you think it says it means) #Winning?:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/13/httpcancer-orgacsgroupscontentepidemiologysurveilancedocumentsdocumentacspc-036845-pdf/
======================================
[3] – 12/21/2006 – On the messiness of evidence-based medicine
——————————————————————
http://scienceblogs.com/insolence/2006/12/21/the-messiness-of-evidencebased-medicine/
======================================
[4] – 9/13/2007 – FDA Approval for Raloxifene Hydrochloride (Brand name(s): Evista®): Approved for breast cancer risk reduction:
——————————————————————
http://www.cancer.gov/cancertopics/druginfo/fda-raloxifene-hydrochloride
======================================
[5] – 9/14/2007 – FDA Approves New Uses for Evista: Drug Reduces Risk of Invasive Breast Cancer in Postmenopausal Women:
——————————————————————
http://www.fda.gov/newsevents/newsroom/pressannouncements/2007/ucm108981.htm
======================================
[6] – 9/17/2007 – Evista Approved for Reducing Breast Cancer Risk:
——————————————————————
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm048474.htm
======================================
[7] – 2007
——————————————————————

Click to access 020815s018lbl.pdf

======================================
[8]
——————————————————————

Click to access ucm088593.pdf

======================================
[9] – 2007
——————————————————————

Click to access 022042lbl.pdf

======================================
[10] – 10/18/2013 – Deconstructing Dr. David H. (Orac) Gorski – September 28, 2013 “The Skeptics™” Burzynski discussion: By Bob Blaskiewicz – 2:19:51
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/10/18/deconstructing-dr-david-h-orac-gorski-september-28-2013-the-skeptics-burzynski-discussion-by-bob-blaskiewicz-21951/
======================================
[11] – 11/4/2013
——————————————————————
http://www.justice.gov/opa/pr/2013/November/13-ag-1170.html
======================================

Count de Money: What Are the Costs of Cancer ? (American Cancer Society Cancer Facts & Figures 2002-2013)

Posted on by
Reply

======================================
What Are the Costs of Cancer?
——————————————————————
National Institutes of Health (NIH) estimates:
——————————————————————
overall costs of cancer:
——————————————————————
2010 – $263.8 billion (2011)
2010☝$263.8 billion (2010)
2008👇$201.5 billion (2013)
2008☝$228.1 billion (2009)
2007☝$226.8 billion (2012)
2007☝$219.2 billion (2008)
2006👇$206.3 billion (2007)
2005☝$209.9 billion (2006)
2004☝$189.8 billion (2005)
2003☝$189.5 billion (2004)
2002☝$171.6 billion (2003)
2001☝$156.7 billion (2002)
——————————————————————
direct medical costs
(total of all health expenditures)
——————————————————————
2010 – $102.8 billion (2011)
2010☝$102.8 billion (2010)
2008👇$77.4 billion (2013)
2008👇$93.2 billion (2009)
2007☝$103.8 billion (2012)
2007☝$89.0 billion (2008)
2006☝$78.2 billion (2007)
2005☝$74.0 billion (2006)
2004☝$69.4 billion (2005)
2003☝$64.2 billion (2004)
2002☝$60.9 billion (2003)
2001☝$56.4 billion (2002)
——————————————————————
2008-2011 – indirect morbidity costs
(cost of lost productivity due to illness)
——————————————————————
2010 – $20.9 billion (2011)
2010☝$20.9 billion (2010)
2008☝$18.8 billion (2009)
2007☝$18.2 billion (2008)
2006☝$17.9 billion (2007)
2005☝$17.5 billion (2006)
2004☝$16.9 billion (2005)
2003☝$16.3 billion (2004)
2002👇$15.5 billion (2003)
2001☝$15.6 billion (2002)
——————————————————————
indirect mortality costs
(cost of lost productivity due to premature death)
——————————————————————
2010 – $140.1 billion (2011)
2010☝$140.1 billion (2010)
2008☝$124.0 billion (2013)
2008👇$116.1 billion (2009)
2007☝$123.0 billion (2012)
2007☝$112.0 billion (2008)
2006👇$110.2 billion (2007)
2005☝$118.4 billion (2006)
2004👇$103.5 billion (2005)
2003☝$109 billion (2004)
2002☝$95.2 billion (2003)
2001☝$84.7 billion (2002)
——————————————————————
According to US Census Bureau:
——————————————————————
Americans uninsured
2012-2013 had no health insurance coverage
——————————————————————
2010👇approximately 50 million (2013)
2009 – almost 51 million (2012)
2009☝almost 51 million (2011)
2008☝46 million (2010)
——————————————————————
2008 – approximately 28% aged 18 to 34 years (2010)
——————————————————————
2010👇almost one-third of Hispanics (31%) (2013)
2009 – almost one-third of Hispanics (32%) (2012)
2009☝almost one­-third of Hispanics (32%) (2011)
——————————————————————
2011-2012 (17 years of age and younger)
2010-2012 – had no health insurance coverage
——————————————————————
2010 – one in 10 children (2013)
2009 – one in 10 children (2012)
2009 – one in 10 children (2011)
2008 – 10% of children (2010)
——————————————————————
2012-2013 PLEASE NOTE:

These numbers are not comparable to those published in previous years as of 2011, NIH calculating estimates using different data source:

2012 – NIH is using a different data source:

2012-2013 Medical Expenditure Panel Survey (MEPS) of the Agency for Healthcare Research and Quality

2012-2013 MEPS estimates based on more current, nationally representative data used extensively in scientific publications

2012-2013 direct and indirect costs will no longer be projected to current year, estimates of indirect morbidity costs discontinued

2012-2013 For more information, please visit nhlbi.nih.gov/about/factpdf.htm.
——————————————————————
Lack of health insurance and other barriers prevents many Americans from receiving optimal health care
——————————————————————
2008 – early release estimates from National Health Interview Survey (2009)
2006 – early release estimates from the National Health Interview Survey (2008)
2004 – National Health Interview Survey data (2007)
2003 – National Health Interview Survey data (2006)
——————————————————————
2008 – about 24% aged 18 to 64 years (2009)
2006☝about 24% aged 18-64 (2008)
2004 – about 17% younger than age 65 had no health insurance coverage (2007)
2003☝about 17% younger than age 65 have no health insurance coverage (2006)
——————————————————————
2004 – 27% 65 and older had Medicare coverage only (2007)
2003☝24% 65 and older have Medicare coverage only (2006)
——————————————————————
2008 – 13% of children had no health insurance coverage for at least part of past year (2009)
2006☝13% of children had no health insurance coverage for at least part of past year (2008)
——————————————————————
2008 – More than 36% of adults who lack high school diploma were uninsured in past year (2009)
2006☝Almost 34% of adults who lack high school diploma were uninsured in past year (2008)
——————————————————————
2008 – 23% of high school graduates (2009)
2006☝23% of high school graduates (2008)
——————————————————————
2008👇14% of those with more than high school education (2009)
2006 – 15% of those with more than high school education (2008)
——————————————————————
2008 – Lack of health insurance is not only a concern of unemployed; almost one-quarter of employed individuals (aged 18 to 64 years) were uninsured sometime during past year (2009)
——————————————————————
2004 – Persons in lowest income group 10 times as likely as persons in highest income group not to receive needed medical care because of cost (2007)
——————————————————————
2004 – Almost 16 million citizens (6%) were unable to obtain needed medical care due to cost (2007)
——————————————————————
2003 – In survey, nearly 20% aged 18-44 years reported not having usual place to go for medical care (2006)
——————————————————————
2010-2013 – Uninsured patients and ethnic minorities substantially more likely to be diagnosed with cancer at later stage, when treatment can be more extensive and more costly
——————————————————————
2012-2013 – For more information on relationship between health insurance and cancer, see Cancer Facts & Figures 2008, Special Section, available online at cancer.org/statistics.
2010 – cancer.org.
2009 – (5008.08), Special Section, available online at cancer.org.
2008 – see special section page 22

20131122-005657.jpg

20131122-005720.jpg

20131122-005738.jpg

20131122-005752.jpg
======================================
REFERENCES:
======================================
2013:
——————————————————————

Click to access acspc-036845.pdf

======================================
2012:
——————————————————————

Click to access acspc-031941.pdf

======================================
2011:
——————————————————————

Click to access acspc-029771.pdf

======================================
2010:
——————————————————————

Click to access acspc-024113.pdf

======================================
2009:
——————————————————————

Click to access 500809webpdf.pdf

======================================
2008:
——————————————————————

Click to access worldcancer.pdf

=====================================
2007:
——————————————————————

Click to access caff2007pwsecuredpdf.pdf

======================================
2006:
——————————————————————

Click to access caff2006pwsecuredpdf.pdf

======================================
2005:
——————————————————————

Click to access caff2005f4pwsecuredpdf.pdf

======================================
2004:
——————————————————————

Click to access CancerRates2004.pdf

======================================
2003:
——————————————————————

Click to access 2003_ACS_Cancer_Facts.pdf

======================================
2002:
——————————————————————

Click to access CancerFacts&Figures2002.pdf

======================================